Vertex Pharmaceuticals: Jim Cramer Fires A Warning Shot But I Remain Invested
Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...
Shareholders that lost money on Vertex Pharmaceuticals Incorporated(VRTX) should contact Levi & Korsinsky about Securities Fraud Investigation - VRTX
NEW YORK, NY / ACCESSWIRE / December 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
Despite the real problems with the additional indication being sought for suzetrigine, this drop in the stock is still an ...
Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors despite daily gains
Shares of Vertex Pharmaceuticals Inc. VRTX inched 0.84% higher to $402.70 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.43 ...
Vertex Pharmaceuticals’ (VRTX) Hold Rating Reiterated at Needham & Company LLC
Needham & Company LLC reaffirmed their hold rating on shares of Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) in a ...
Yahoo Finance7d
Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $408.18, moving +0.72% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 1.1%.
Vertex Pharmaceuticals: Alyftrek Is An 'Accretive Opportunity' On Top- And Bottom-Lines, Says Bullish Analyst
Vertex Pharmaceuticals announced FDA approval for Alyftrek, which expands the company's CF franchise to address around 6,000 ...
MarketWatch12d
Vertex Pharmaceuticals Shares Drop on Mixed Results in Drug Trial
Vertex Pharmaceuticals shares fell after the company reported mixed results from a study of a treatment for patients with lumbosacral radiculopathy, a neurological disorder that causes back and ...
Yahoo Finance5d
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to ...